After hosting investor meetings with the company's CEO Mike Minogue, CFO Mike Tomsicek, and Director of IR Ingrid Goldberg, Leerink analyst Danielle Antalffy remains confident that Abiomed's fundamentals are intact, and the company remains on a "hyper-growth trajectory" with significant positive operating leverage. The analyst remains confident in a sustainable long-term "strong" double-digit growth trajectory built on a market-leading product, a large and still-expanding salesforce, and a "strong" foundation of clinical evidence. She reiterates an Outperform rating and $140 price target on the shares.